Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia

Background: Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited.

Objectives: This article describes clinical guidelines for the administration of moxetumomab pasudotox to patients with R/R HCL and presents related case studies.

Methods: A limited review of the literature on HCL was undertaken.

Findings: Nursing care of patients prescribed moxetumomab pasudotox includes monitoring clinical and laboratory parameters, managing side effects, being aware of signs of serious side effects, and maintaining patient hydration during administration.